Pharmafile Logo
Pharmafocus logo
Advanced Search

diabetes

Showing 15 posts of 381 posts found.

novo_nordisk_flag

Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3

November 26, 2018
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide

Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …

News
diabetes-777001_960_720

3 in 4 UK diabetes patients suffer from mental health issues, says report

November 14, 2018
Medical Communications, Research and Development UK, World Diabetes Day, diabetes, pharma

To mark this year’s World Diabetes Day on 14 November, a new report has shed more light on the psychological …

News

NHS diabetes prescriptions top £1 billion a year

November 9, 2018
Medical Communications, Sales and Marketing Health Education England, NHS, UK, diabetes, pharma

The NHS in England is now spending over £1billion a year on diabetes prescriptions, almost doubling in the last decade, …

News

Galectin-3: The protein paving new treatment avenues

November 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Galectin-3, Galectins, breast cancer, diabetes, heart disease, pharma

Matthew Blakeley, LADI-III Beamline Scientist at Institut Laue-Langevin (ILL) and Derek Logan, Associate Professor in Structural Biology at Lund University, …

Feature
eye2

Common diabetes drug can protect against age-related macular degeneration, research shows

October 31, 2018
Research and Development age-related macular degeneration, diabetes, eye, metformin, pharma

A Taiwanese research team has demonstrated a link between the use of the common diabetes medication metformin and significantly lower …

News
slimming-2728331_960_720

Effective preventative therapies for type 2 diabetes are underused, new research argues

October 30, 2018
Manufacturing and Production, Research and Development, Sales and Marketing diabetes, obesity, pharma, prediabetes, type 2 diabetes

New research has warned that interventions which can effectively delay or prevent the development of type 2 diabetes are not …

News
merckwindow_web

MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes

October 15, 2018
Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma

MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …

News
novo_flag

Novo Nordisk’s Fiasp shows strong blood sugar control in under-18 type 1 diabetes patients

October 12, 2018
Medical Communications, Research and Development Fiasp, Novo Nordisk, Type 1 diabetes, diabetes, pharma

New data unveiled by Novo Nordisk has shown that its insulin injection Fiasp (fast-acting insulin aspart) could provide a better …

News
astrazeneca-sign

AstraZeneca’s Farxiga cuts heart risk in type 2 diabetes patients

September 24, 2018
Research and Development, Sales and Marketing AstraZeneca, diabetes, farxiga, pharma

AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings …

News
astrazeneca_building_white

AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes

August 30, 2018
Research and Development, Sales and Marketing AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes

AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for …

News
bristol_university_from_cabot_tower

Novo Nordisk buys Bristol University biotech in £620m deal

August 22, 2018
Research and Development Bristol, Novo Nordisk, Ziylo, diabetes

Novo Nordisk has bought a tiny biotech company spun out of Bristol University in a deal that could be worth …

News
novo_nordisk_flag

Novo’s semaglutide hits the mark in Phase 3 type 2 diabetes study

August 21, 2018
Manufacturing and Production, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of …

News

More children suffering from type 2 diabetes in England and Wales

August 20, 2018
Sales and Marketing England, NHS, Wales, children, diabetes, obesity, young people

The number of children and young people suffering from type-2 diabetes has increased in England in Wales over the past …

News
diabetes-777001_960_720

Researchers successfully minimise diabetes drug side-effects in animal models

July 17, 2018
Manufacturing and Production, Research and Development FDA, diabetes, pharma, type 2 diabetes

Researchers at the University of Pennsylvania and Syracuse University have modified a key ingredient of current diabetes drugs to produce …

News

Sanofi’s Toujeo proves non-inferior to insulin degludec in type 2 diabetes

June 26, 2018
Manufacturing and Production, Research and Development, Sales and Marketing American Diabetes Association, Sanofi, diabetes, insulin glargine, pharma, toujeo, type 2 diabetes

Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023